A positive approach to partnering




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: A positive approach to partnering
Released on: November 20, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Since Pascal Soriot's appointment to CEO 2 years ago, AstraZeneca have accelerated their restructuring of research and development, with a rigorous emphasis on streamlining the product portfolio to focus on three core areas, namely, Cancer, Cardiovascular disease, and Respiratory, Inflammation & Auto-Immune disorders.
  • Summary
  • Transcript
  • Participants
  • Company
Since Pascal Soriot's appointment to CEO 2 years ago, AstraZeneca have accelerated their restructuring of research and development, with a rigorous emphasis on streamlining the product portfolio to focus on three core areas, namely, Cancer, Cardiovascular disease, and Respiratory, Inflammation & Auto-Immune disorders. Shaun Grady, VP, Business Development and Operations at AstraZeneca, talks to Fintan Walton, CEO of PharmaVentures, about the ongoing portfolio review which aims to prioritise AstraZeneca's core areas of focus, while creating value for shareholders through strategic divestment and out-partnering.
Since Pascal Soriot's appointment to CEO 2 years ago, AstraZeneca have accelerated their restructuring of research and development, with a rigorous emphasis on streamlining the product portfolio to focus on three core areas, namely, Cancer, Cardiovascular disease, and Respiratory, Inflammation & Auto-Immune disorders. Shaun Grady, VP, Business Development and Operations at AstraZeneca, talks to Fintan Walton, CEO of PharmaVentures, about the ongoing portfolio review which aims to prioritise AstraZeneca's core areas of focus, while creating value for shareholders through strategic divestment and out-partnering.
Shaun Grady has global responsibility for the Strategic Partnering and Business Development (SPBD) function, dedicated to broadening AstraZeneca’s access to scientific innovation outside our own laboratories - a key strategic priority for AstraZeneca. The scope of Shaun’s team includes in-licencing, acquisition and partnering activities from early stage Discovery through to on-market commercial opportunities. Shaun was appointed to his current role, VP SPBD, in 2010. Prior to this he was VP Corporate Business Development from 2006. Shaun originally joined ICI as an attorney and held positions in the Pharmaceuticals, Petrochemicals, and Head Office Legal Departments. Upon the demerger of Zeneca from ICI he was appointed Assistant General Counsel, Corporate. Shaun worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. In addition, he has spent time in the US Business managing a Legal Team and also completed a two year secondment to HR, leading a global People Strategy change project. Shaun enjoys rugby and soccer, and occasionally turns his hand to sports writing.
AstraZeneca
AstraZeneca plc is a British-Swedish pharmaceutical company formed on 6 April 1999 by the remerger of Swedish Astra AB and British Zeneca Group plc. Zeneca had been part of Imperial Chemical Industries (ICI), as three divisions that were spun off from ICI on 1 June 1993. It is a public company and is listed on the London Stock Exchange, the New York Stock Exchange and the OMX exchange.